Access is limited by regulation, so a personalized, physician-supervised protocol with ongoing lab monitoring is essential for safe, realistic results
Domestic pharmaceutical companies are investing in GLP-1 analog manufacturing, driven by: Rising diabetes and obesity prevalence Government focus on affordable healthcare Established biosimilar capabilities Recent trends include: Early-stage launches of GLP-1 analog generics by Indian manufacturers Increased partnerships between global and Indian firms Expansion of domestic manufacturing capacity These developments will significantly boost local demand for drug delivery devices, particularly low-cost injection systems
( 10.1016/S0140-6736(1931149-3) [DOI] [PubMed] [Google Scholar] Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, et al
The most common methods include: Injectable Peptides The most effective delivery method for systemic benefits
And it's such an important conversation
